戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 cardiac foramen ovale, or elevated levels of antiphospholipid antibody.
2 ctive protein (CRP), and the presence of any antiphospholipid antibody.
3 after renal transplantation in patients with antiphospholipid antibodies.
4 disease activity, emotional disturbance, and antiphospholipid antibodies.
5  recurrent pregnancy failure associated with antiphospholipid antibodies.
6 tion on noncellular phospholipid surfaces by antiphospholipid antibodies.
7  the reduction of surface-bound annexin V by antiphospholipid antibodies.
8 of lupus pregnancy, especially in women with antiphospholipid antibodies.
9 tions in patients with persistently positive antiphospholipid antibodies.
10 ination of aspirin and heparin in women with antiphospholipid antibodies.
11 ity in the presence of persistently positive antiphospholipid antibodies.
12 hrombotic risk in asymptomatic patients with antiphospholipid antibodies.
13 al anticoagulant and fibrinolytic systems by antiphospholipid antibodies.
14 factor VII mutation, factor II mutation, and antiphospholipid antibodies.
15 ished by the 13th International Committee on Antiphospholipid Antibodies.
16  or at risk of, thrombosis in the setting of antiphospholipid antibodies.
17 cular complications of lupus associated with antiphospholipid antibodies.
18 ffective for nonthrombotic manifestations of antiphospholipid antibodies.
19 coprotein I (beta2GPI), the main antigen for antiphospholipid antibodies.
20 ting to detect treponemal and nontreponemal (antiphospholipid) antibodies.
21 w that ApoER2 is involved in pathogenesis of antiphospholipids antibodies.
22                                          The Antiphospholipid Antibody Acetylsalicylic Acid (APLASA)
23            To test this idea, we studied how antiphospholipid antibodies affect levels of annexin V o
24                                              Antiphospholipid antibodies and CRP support the role of
25 mbocytopenia associated with the presence of antiphospholipid antibodies and persistently positive an
26 lar endothelial cell dysfunction mediated by antiphospholipid antibodies and subsequent complement sy
27 mbotic status of APS patients induced by IgG-antiphospholipid antibodies and the beneficial effects o
28                  Patients without persistent antiphospholipid antibodies and whose thrombi were resol
29 ress with regard to the relationship between antiphospholipid antibody and its target, beta-2-glycopr
30 basis of prothrombin recognition by a type I antiphospholipid antibody and uncover an exciting new st
31 n I (beta2GPI; the major autoantigen for the antiphospholipid antibodies) and the homologous catalyti
32 c lupus erythematosus (SLE), 2 patients with antiphospholipid antibodies, and 3 other patients, but a
33 re corticosteroid treatment, the presence of antiphospholipid antibodies, and acute thrombocytopenia.
34 limitations of existing laboratory tests for antiphospholipid antibodies, and the absence of evidence
35 levant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS-A and anti-La/
36                                 Antinuclear, antiphospholipid antibodies, anti-Ro, and anti-La antibo
37 trap (NET) release is one mechanism by which antiphospholipid antibodies (aPL Abs) effect thrombotic
38 erosclerosis have an increased prevalence of antiphospholipid antibodies (aPL) and antibodies to oxid
39                                     Although antiphospholipid antibodies (aPL) are associated with ar
40                                   Pathogenic antiphospholipid antibodies (aPL) bind the self antigen
41          In antiphospholipid syndrome (APS), antiphospholipid antibodies (aPL) binding to beta2 glyco
42                              The presence of antiphospholipid antibodies (aPL) has been associated wi
43                                              Antiphospholipid antibodies (aPL) have been shown to ind
44                                              Antiphospholipid antibodies (aPL) have thrombogenic prop
45             To test the hypothesis that some antiphospholipid antibodies (aPL) in patients with the a
46                                              Antiphospholipid antibodies (aPL) in primary or secondar
47                It is also the main target of antiphospholipid antibodies (aPL) in the acquired coagul
48    The mechanism leading to the formation of antiphospholipid antibodies (aPL) is still unknown.
49 phospholipid syndrome (APS), suggesting that antiphospholipid antibodies (aPL) may bind platelets, ca
50                                        Serum antiphospholipid antibodies (aPL) were identified by ant
51 ients had APS, 24 patients were positive for antiphospholipid antibodies (aPL), and 19 patients had S
52 ion with these mutations and the presence of antiphospholipid antibodies (aPL), lupus anticoagulant (
53 a condition characterized by the presence of antiphospholipid antibodies (aPL), often suffer pregnanc
54 ns developing in individuals with persistent antiphospholipid antibodies (aPL).
55 ospholipid syndrome, our approach focused on antiphospholipid antibodies (aPL).
56 poorly known, particularly in the absence of antiphospholipid antibodies (APL).
57 ipid syndrome (APS), our approach focused on antiphospholipid antibodies (aPL).
58 d laboratory confirmation of the presence of antiphospholipid antibodies (aPL).
59 hat has been associated with the presence of antiphospholipid antibodies (aPL).
60 to PON1 activity, SLE risk, lupus nephritis, antiphospholipid antibody (aPL) positivity, and carotid
61  action of WIG in an in vivo murine model of antiphospholipid antibody (aPL)-induced thrombosis and e
62 sis prevention in asymptomatic, persistently antiphospholipid antibody (aPL)-positive individuals (th
63 y was to evaluate the safety of rituximab in antiphospholipid antibody (aPL)-positive patients with n
64 physicians in the management of persistently antiphospholipid antibody (aPL)-positive patients.
65                       Laboratory evidence of antiphospholipid antibodies (APLA) in patients with a fi
66      Although not all patients with elevated antiphospholipid antibody (aPLA) levels develop complica
67                                Patients with antiphospholipid antibodies (APLAs) are at increased ris
68 is and recurrent fetal loss in patients with antiphospholipid antibodies (APLAs).
69  recurrent pregnancy loss in the presence of antiphospholipid antibodies (APLAs).
70                                              Antiphospholipid antibodies (aPLs) cause severe autoimmu
71 se it binds phospholipids, it is a target of antiphospholipid antibodies (aPLs) in antiphospholipid s
72                        Fetal loss induced by antiphospholipid antibodies (aPLs) in mice is a compleme
73    There are few data on the relationship of antiphospholipid antibodies (aPLs) to pathologically pro
74                                              Antiphospholipid antibodies (aPLs) with complex lipid an
75                                              Antiphospholipid antibodies are associated with arterial
76                Patients who have circulating antiphospholipid antibodies are at risk for major abdomi
77                                              Antiphospholipid antibodies are commonly found in patien
78 d detected in clinical laboratory assays for antiphospholipid antibodies are directed against prothro
79 (n = 513; LMWH + LDA) and women negative for antiphospholipid antibodies as controls (n = 791; no tre
80 utcome in women with a history of refractory antiphospholipid antibody-associated pregnancy loss(es)
81                                Two cases had antiphospholipid antibodies but none had PF4 antibodies.
82 n with aspirin is justified in patients with antiphospholipid antibodies but without a prior history
83                                              Antiphospholipid antibodies can be detected in roughly 5
84                                 The field of antiphospholipid antibodies continues to evolve, with ma
85 a component and suggest that the epitopes of antiphospholipid antibodies could include CL or oxidized
86 bset of periodontitis patients with elevated antiphospholipid antibodies could represent a subgroup a
87        Anticoagulation, prednisone dose, and antiphospholipid antibodies did not significantly impact
88 y of stroke, migraine with aura, circulating antiphospholipid antibodies, discontinuation of antiplat
89                                              Antiphospholipid antibodies disrupt AnxA5 binding, there
90  the mechanism of thrombosis associated with antiphospholipid antibodies found in the rheumatic disea
91                                          The antiphospholipid antibodies found in this syndrome are d
92 ment, but also regarding the pathogenesis of antiphospholipid antibodies, has emerged.
93 gs of yellow scleral plaques and circulating antiphospholipid antibodies have been proposed as marker
94 rophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG as compared with control I
95 rophoblasts and endothelial cells exposed to antiphospholipid-antibody IgG had faster mean (+/- SE) p
96 onucleoprotein antibodies in 26 percent, and antiphospholipid antibodies in 18 percent.
97                                  The role of antiphospholipid antibodies in ocular disease has receiv
98 PS) is defined by the persistent presence of antiphospholipid antibodies in patients with a history o
99 een conducted to determine the prevalence of antiphospholipid antibodies in patients with retinal vas
100                                              Antiphospholipid antibodies in SLE are associated with m
101                                  The role of antiphospholipid antibodies in the pathogenesis of SLE m
102                                              Antiphospholipid antibodies including anticardiolipin an
103  thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti-beta2-glycop
104 nd/or pregnancy morbidity in the presence of antiphospholipid antibodies, including anti-beta2-glycop
105                                              Antiphospholipid antibodies, including anticardiolipin a
106 patients with key clinical manifestations of antiphospholipid antibodies, including patients with ant
107 ion discusses novel pathogenic mechanisms of antiphospholipid antibodies, including the activation of
108 ll lines, wherein HCQ reduced the binding of antiphospholipid antibodies, increased cell-surface AnxA
109                The presence of pretransplant antiphospholipid antibodies increases risk of graft thro
110    Delineation of the epitopes recognized by antiphospholipid antibodies induced by HIV-1 offers insi
111                      These studies show that antiphospholipid antibodies interfere with the binding o
112 of thrombosis and gestational morbidity with antiphospholipid antibodies is termed antiphospholipid s
113 n of disease, hypertension, body mass index, antiphospholipid antibodies, kidney disease, acute throm
114 imer test after stopping anticoagulation, an antiphospholipid antibody, low risk of bleeding, and pat
115 (P = 0.04) and were also more likely to have antiphospholipid antibodies (lupus anticoagulant) (P = 0
116 e setting of persistently positive levels of antiphospholipid antibodies measured on 2 different occa
117                     The induction of ET-1 by antiphospholipid antibodies might contribute to increase
118                  Therefore, we asked whether antiphospholipid antibodies might directly reduce annexi
119         The molecular pathways through which antiphospholipid antibodies modulate the mTORC pathway w
120 gh genetic loss of KLF2 or administration of antiphospholipid antibodies, neutrophils clustered P-sel
121                   HCQ reversed the effect of antiphospholipid antibodies on AnxA5 and restored AnxA5
122 utrophils and platelets with patient-derived antiphospholipid antibodies or ectonucleotidase inhibito
123                             The elevation of antiphospholipid antibodies predicted early infection wi
124 otein I (beta(2)-GPI) is a major antigen for antiphospholipid antibodies present in patients with the
125  Coma Scale score, intracranial haemorrhage, antiphospholipid antibodies, previous major bleeding, an
126 nd patients with immune thrombocytopenia and antiphospholipid antibodies, previous thrombotic events,
127                                              Antiphospholipid antibody profiles and clinical outcome
128                                              Antiphospholipid antibodies reduce the levels of annexin
129         Also, exposure to plasmas containing antiphospholipid antibodies reduces annexin-V binding to
130 r assessment in the management of refractory antiphospholipid antibody-related pregnancy loss(es), al
131                                              Antiphospholipid antibodies remain one of the more commo
132 antibody-positive patients, although lacking antiphospholipid antibodies, shared an amino acid epitop
133                                              Antiphospholipid antibodies should be sought in all pati
134 r V Leiden, prothrombin 20210A mutation, and antiphospholipid antibodies significantly increases a pa
135  the first direct evidence that a particular antiphospholipid antibody specificity may contribute to
136                                              Antiphospholipid antibody syndrome (APAS) is characteriz
137 End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high
138                                        Using antiphospholipid antibody syndrome (APS) as a model for
139                                              Antiphospholipid antibody syndrome (APS) is a complex au
140 optimal clinical management of patients with antiphospholipid antibody syndrome (APS) is uncertain be
141                            Patients with the antiphospholipid antibody syndrome (APS) often experienc
142 potential role of new oral anticoagulants in antiphospholipid antibody syndrome (APS) remains uncerta
143 cardiolipin (CL), are found in patients with antiphospholipid antibody syndrome (APS).
144 es that were all isolated from patients with antiphospholipid antibody syndrome (APS); testing was al
145                       New antibody tests for antiphospholipid antibody syndrome are available with in
146 wledge of the clinical syndrome that we call antiphospholipid antibody syndrome has also progressed.
147  understanding of the pathophysiology behind antiphospholipid antibody syndrome has led to novel appr
148 idelines for the treatment and management of antiphospholipid antibody syndrome have been established
149                   The diagnostic criteria of antiphospholipid antibody syndrome have been reviewed an
150                                          The antiphospholipid antibody syndrome is an important cause
151                                              Antiphospholipid antibody syndrome with valvular vegetat
152 rment within SLE and related conditions (eg, antiphospholipid antibody syndrome, active vs inactive S
153 and autoimmune conditions, such as lupus and antiphospholipid antibody syndrome, and, more recently,
154 iolipin (anti-CL) antibodies, diagnostic for antiphospholipid antibody syndrome, are associated with
155 plant-associated thrombotic microangiopathy, antiphospholipid antibody syndrome, myasthenia gravis, a
156 er pertaining to anticoagulant choice, as in antiphospholipid antibody syndrome, or to addressing a n
157 d cause valvular vegetations associated with antiphospholipid antibody syndrome, which would be a new
158 l hemolytic uremic syndrome and catastrophic antiphospholipid antibody syndrome.
159 e appropriate laboratory results make up the antiphospholipid antibody syndrome.
160 id-binding protein and an autoantigen in the antiphospholipid antibody syndrome.
161 ociated with thrombosis in patients with the antiphospholipid antibody syndrome.
162 ave also updated information about pediatric antiphospholipid antibody syndrome.
163  and relapse of autoimmune diseases, such as antiphospholipid antibody syndrome.
164 pholipid antibodies, including patients with antiphospholipid antibody syndrome.
165 d IgG fractions from three patients with the antiphospholipid-antibody syndrome and from normal contr
166 ascular thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome are unknown.
167 nism of thrombosis and pregnancy loss in the antiphospholipid-antibody syndrome.
168                                              Antiphospholipid antibodies targeting beta2-glycoprotein
169        Routine laboratory, autoantibody, and antiphospholipid antibody testing was performed in the h
170 reincubation of healthy monocytes before IgG-antiphospholipid antibody treatment decreased oxidative
171  the molecular and intracellular events that antiphospholipid antibodies trigger in target cells, as
172 actions and the intracellular signaling that antiphospholipid antibodies trigger, new therapeutic and
173 rrent pregnancy loss includes measurement of antiphospholipid antibodies under the perception that th
174                                              Antiphospholipid antibody was present in a titer of 1:10
175                                     Rates of antiphospholipid antibodies were low, comparable to thos
176                                           No antiphospholipid antibodies were present in the patient'
177                                              Antiphospholipid antibodies were present(defined as IgG
178 olytic anemia, anti-double-stranded DNA, and antiphospholipid antibody were associated with thrombocy
179 pus erythematosus occurs in association with antiphospholipid antibodies, which also are associated w
180 d with high levels of C-reactive protein and antiphospholipid antibodies, which impeded coagulation i
181 or V antibody not related to the presence of antiphospholipid antibodies, which is responsible for th
182                          Eighteen women with antiphospholipid antibodies who had refractory pregnancy
183 ion on biopsy as compared with patients with antiphospholipid antibodies who were not receiving sirol
184  patients, and 0 of 5 cycles in 2 women with antiphospholipid antibody (without SLE or primary APS) r

 
Page Top